Goldman Sachs’s Viking Therapeutics VKTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $31.3M | Buy |
960,570
+127,919
| +15% | +$4.11M | ﹤0.01% | 2016 |
|
|
2025
Q4 | $29.3M | Buy |
832,651
+564,907
| +211% | +$20M | ﹤0.01% | 1998 |
|
|
2025
Q3 | $7.04M | Buy |
267,744
+114,326
| +75% | +$3.41M | ﹤0.01% | 3321 |
|
|
2025
Q2 | $4.07M | Buy |
153,418
+14,063
| +10% | +$370K | ﹤0.01% | 3607 |
|
|
2025
Q1 | $3.37M | Buy |
139,355
+37,653
| +37% | +$1.19M | ﹤0.01% | 3728 |
|
|
2024
Q4 | $4.09M | Sell |
101,702
-55,017
| -35% | -$3.14M | ﹤0.01% | 3653 |
|
|
2024
Q3 | $9.92M | Sell |
156,719
-917,481
| -85% | -$53.8M | ﹤0.01% | 2737 |
|
|
2024
Q2 | $56.9M | Buy |
1,074,200
+432,004
| +67% | +$28.3M | 0.01% | 1078 |
|
|
2024
Q1 | $52.7M | Sell |
642,196
-477,689
| -43% | -$21.3M | 0.01% | 1137 |
|
|
2023
Q4 | $20.8M | Buy |
1,119,885
+525,296
| +88% | +$6.87M | ﹤0.01% | 1840 |
|
|
2023
Q3 | $6.58M | Sell |
594,589
-98,273
| -14% | -$1.41M | ﹤0.01% | 2749 |
|
|
2023
Q2 | $11.2M | Buy |
692,862
+19,076
| +3% | +$400K | ﹤0.01% | 2334 |
|
|
2023
Q1 | $11.2M | Buy |
673,786
+594,066
| +745% | +$6.14M | ﹤0.01% | 2316 |
|
|
2022
Q4 | $749K | Buy |
79,720
+42,685
| +115% | +$191K | ﹤0.01% | 4617 |
|
|
2022
Q3 | $101K | Sell |
37,035
-20,322
| -35% | -$66.6K | ﹤0.01% | 5682 |
|
|
2022
Q2 | $166K | Sell |
57,357
-202,992
| -78% | -$502K | ﹤0.01% | 5704 |
|
|
2022
Q1 | $781K | Buy |
260,349
+173,352
| +199% | +$622K | ﹤0.01% | 5018 |
|
|
2021
Q4 | $400K | Sell |
86,997
-53,614
| -38% | -$300K | ﹤0.01% | 5511 |
|
|
2021
Q3 | $883K | Sell |
140,611
-151,370
| -52% | -$935K | ﹤0.01% | 4843 |
|
|
2021
Q2 | $1.75M | Buy |
291,981
+242,938
| +495% | +$1.44M | ﹤0.01% | 4328 |
|
|
2021
Q1 | $310K | Sell |
49,043
-28,727
| -37% | -$202K | ﹤0.01% | 5410 |
|
|
2020
Q4 | $438K | Sell |
77,770
-547,254
| -88% | -$3.31M | ﹤0.01% | 4687 |
|
|
2020
Q3 | $3.64M | Buy |
625,024
+48,870
| +8% | +$336K | ﹤0.01% | 3133 |
|
|
2020
Q2 | $4.15M | Buy |
576,154
+492,965
| +593% | +$3.27M | ﹤0.01% | 2937 |
|
|
2020
Q1 | $389K | Sell |
83,189
-59,566
| -42% | -$366K | ﹤0.01% | 4360 |
|
|
2019
Q4 | $1.15M | Buy |
142,755
+47,213
| +49% | +$344K | ﹤0.01% | 4038 |
|
|
2019
Q3 | $657K | Buy |
95,542
+66,298
| +227% | +$492K | ﹤0.01% | 4302 |
|
|
2019
Q2 | $243K | Sell |
29,244
-35,951
| -55% | -$307K | ﹤0.01% | 4701 |
|
|
2019
Q1 | $648K | Sell |
65,195
-155,253
| -70% | -$1.3M | ﹤0.01% | 4284 |
|
|
2018
Q4 | $1.69M | Buy |
220,448
+115,709
| +110% | +$1.38M | ﹤0.01% | 3634 |
|
|
2018
Q3 | $1.82M | Sell |
104,739
-10,357
| -9% | -$123K | ﹤0.01% | 3662 |
|
|
2018
Q2 | $1.09M | Sell |
115,096
-96,333
| -46% | -$641K | ﹤0.01% | 4014 |
|
|
2018
Q1 | $924K | Buy |
+211,429
| New | +$1.17M | ﹤0.01% | 4105 |
|
|
2017
Q1 | – | Sell |
-29,239
| Closed | -$35K | – | 7021 |
|
|
2016
Q4 | $35K | Buy |
+29,239
| New | +$33K | ﹤0.01% | 6485 |
|
|
2016
Q1 | – | Sell |
-12,826
| Closed | -$44K | – | 7346 |
|
|
2015
Q4 | $44K | Sell |
12,826
-5,436
| -30% | -$24.4K | ﹤0.01% | 6607 |
|
|
2015
Q3 | $107K | Sell |
18,262
-5,432
| -23% | -$34.9K | ﹤0.01% | 6441 |
|
|
2015
Q2 | $169K | Buy |
+23,694
| New | +$196K | ﹤0.01% | 6272 |
|
Other funds holding VKTX
VCM
VPM
Goldman Sachs's VKTX Position: Q1 2026 in Review
Goldman Sachs increased its Viking Therapeutics (VKTX) stake by 15% in Q1 2026, buying an estimated $4.11M and bringing the position to 960,570 shares worth $31.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2016.
Goldman Sachs first reported a position in VKTX in Q2 2015 and has held it in 37 quarters since. The position peaked at $56.9M in Q2 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.
- Goldman Sachs held 960,570 shares of Viking Therapeutics worth $31.3M as of Q1 2026.
- Goldman Sachs bought 127,919 Viking Therapeutics shares in Q1 2026, an estimated $4.11M.
- Viking Therapeutics made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #2016 holding.
- Goldman Sachs first reported a position in Viking Therapeutics in Q2 2015 and has held it in 37 quarters since.
- Goldman Sachs's Viking Therapeutics position peaked at $56.9M in Q2 2024.
- 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.
Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.